Based on this assumption, we treated cRCC cells with MG132, an inhibitor of the proteasome, and the results revealed that the upregulation of PEBP1 protein mediated by circPOLR2A knockdown could be counteracted by MG132 (Fig. 5a). Here, PEBP1 is linked to chromophobe renal cell carcinoma.